GLP-1 Results In Shocking Drop In Sick Leave?!

Medication blister pack, insulin pens, and tape measure on a gray surface — GLP-1 RESULTS SHOCKER

A new economic study says popular GLP-1 drugs are not just shrinking waistlines—they are slashing long-term worker sick leave by more than one-sixth and quietly rewriting the math of workplace productivity.

Story Snapshot

Researchers find GLP-1 treatment is linked to a 17.3% drop in long-term sickness leave among workers.
Long-term sick leave in the study means being off work more than 30 days for health reasons.
The reduction in sick leave translates into fiscal benefits equal to about 1.3% to 1.5% of annual labor income for treated workers.
The study adds fuel to a growing debate over whether employers should pay for costly GLP-1 drugs to boost workforce health.

Researchers connect GLP-1 treatment to fewer long sick leaves

Researchers from universities in Copenhagen, Chicago, and Duke dug into nationwide data from Denmark to see what happens at work when people start GLP-1 drugs like Ozempic and Wegovy.

They tracked employed adults who began treatment and compared them with similar patients who did not start the drugs until later.

The team focused on medically certified sick leave lasting more than 30 days, the kind of absence that signals serious health trouble and heavy costs for workers and employers.

The working paper reports that GLP-1 treatment reduces long-term sickness leave by 17.3% over four years. In practical terms, that is a drop of 0.95 percentage points from a pre-treatment average of 5.5% of workers taking long sick spells.

Put simply, if you had 100 similar workers, about five or six were having long medical absences before treatment; after GLP-1 therapy, that number falls by roughly one in five. For large employers, that change compounds quickly into fewer disruptions and more time on the job.

Economic impact reaches beyond the clinic

The authors do not stop at counting sick days; they turn those days into hard currency. The study estimates total fiscal benefits of GLP-1 initiation at about 1.3% to 1.5% of annual labor income per employed patient. Media coverage translates that figure into roughly 866 dollars per worker in average yearly savings tied to lower long-term sick leave.

That is not a miracle windfall, but for a mid-size company with hundreds of covered employees, it quickly reaches six figures. For policymakers, those numbers hint at reduced strain on public sickness benefits and disability systems.

The effect also grows over time. Early in treatment, the drop in long-term sick leave is around 0.8 percentage points, then widens to about 1.1 percentage points in years three and four.

That pattern fits what doctors see: sustained GLP-1 use improves blood sugar, weight, and pressure over many months, which then lowers risk for heart disease and other chronic problems.

When those conditions ease, workers spend fewer long stretches out of the labor force, and the tax base is stronger. That is the kind of long-game health payoff that appeals to fiscally thinkers focused on work, responsibility, and self-sufficiency.

Broader evidence shows health care and productivity are tightly linked

This GLP-1 paper lands in a research field that has been building for years: better treatment for chronic disease often lines up with better work outcomes.

A multi-employer study in the United States found that health-related productivity costs—lost days and underperformance at work—run about 2.3 times higher than direct medical and pharmacy costs.

That means a dollar spent on a worker’s health problem can quietly drag two to four dollars out of the employer’s bottom line through missed work and lower output.

Other studies show that new drug treatments can improve ability to work by as much as 60% for certain conditions. Reviews of medication adherence find mixed results, but they consistently show that when people stick with needed treatment, short-term disability and absenteeism can drop in meaningful ways.

Against that backdrop, the 17.3% reduction in long-term sick leave seen with GLP-1 therapy is not a wild outlier; it is part of a larger pattern where smarter health care spending can protect jobs, families, and business performance.

GLP-1 drugs also touch costs, morale, and employer risk

Consulting firms now report that sustained use of GLP-1 therapies can slow medical cost growth by 3% to 9%, depending on whether the drugs are used for diabetes or weight loss.

At the same time, GLP-1 medications are expensive, often running hundreds of dollars per member per month, and no federal law requires employers to cover them for weight loss.

Large employers have been cautious; only about one in five say their main health plan covers GLP-1s primarily for weight loss, with higher coverage rates among very large firms.

GLP-1 drugs linked to 17% drop in worker sick leave, new economic study finds. https://t.co/h3Jjwf2KAI

— CBS News (@CBSNews) July 22, 2026

A separate study warns that yanking GLP-1 coverage after people start treatment can backfire. Workers who lost coverage for obesity medications reported feeling devalued by their employers, more burned out, and more likely to consider changing jobs. For companies already worried about turnover and disengagement, that is a serious red flag.